What is the initial workup for suspected Sjögren’s syndrome?

Workup for Sjögren's Syndrome

When Sjögren's syndrome is suspected based on dry eyes and/or dry mouth, the workup should include a complete serological panel (anti-SSA/Ro, anti-SSB/La, RF, ANA), objective testing of lacrimal and salivary gland function (Schirmer test, ocular surface staining, unstimulated salivary flow), and consideration of minor salivary gland biopsy to achieve the diagnostic threshold of ≥4 points using the ACR/EULAR classification criteria. 1

Initial Clinical Assessment

Key Symptoms to Elicit

Ocular manifestations:

• Persistent eye dryness, grittiness, or foreign body sensation 1
• Burning or stinging sensations 1
• Light sensitivity (photophobia) 1
• Fluctuating or blurred vision 1
• Frequent need for artificial tears 1

Oral manifestations:

• Need for liquids to swallow dry foods 1
• Frequent sipping or drinking of water 1
• Burning sensation in mouth 1
• Angular cheilitis (painful sores at mouth corners) 1
• Rapid onset of dental cavities or gum recession 1, 2

Systemic manifestations:

• Extreme fatigue 1
• Joint or muscle pain (arthralgias/myalgias) 1
• Parotid or submandibular gland swelling 2
• Raynaud phenomenon 2
• Vaginal dryness 1
• Chronic dry cough (present in ~38% of patients) 1, 2
• Peripheral neuropathy (numbness, burning in extremities) 1

Physical Examination Findings

Slit-lamp biomicroscopy should assess:

• Reduced tear meniscus height 1
• Abnormal tear break-up time and pattern 1
• Punctate staining with fluorescein or lissamine green 1
• Conjunctival hyperemia 1
• Mucous strands or discharge 1

External examination should evaluate:

• Lacrimal gland enlargement 1
• Parotid or submandibular gland swelling 2
• Joint deformities (if secondary Sjögren's suspected) 1
• Raynaud phenomenon 1

Serological Testing

Complete autoantibody panel (mandatory):

• Anti-SSA/Ro antibodies (scores 3 points if positive) 1, 3
• Anti-SSB/La antibodies 3, 2
• Rheumatoid factor (RF) (positive in 30% of patients) 3, 2
• Antinuclear antibody (ANA) (positive in 57% of patients) 3, 2

Important caveats:

• Anti-SSA/Ro positivity alone is insufficient for diagnosis but becomes highly significant when combined with clinical manifestations 3
• Traditional biomarkers have low specificity and may be negative in early disease 4
• Point-of-care testing including salivary protein 1 (SP1), carbonic anhydrase 6 (CA6), and parotid secretory protein (PSP) may indicate early Sjögren's when traditional antibodies are negative 1, 4

Objective Glandular Function Testing

Ocular Surface Assessment (1 point each toward diagnosis)

Test	Positive Threshold	Points
Schirmer test (without anesthesia)	≤5 mm/5 minutes	1 [1]
Ocular surface staining (lissamine green or fluorescein)	≥5 OSS or ≥4 van Bijsterveld score	1 [1]

Additional objective tests:

• Tear film osmolarity measurement 1
• Point-of-care matrix metalloproteinase-9 testing 1
• Tear break-up time assessment 1

Salivary Gland Assessment (1 point toward diagnosis)

• Unstimulated whole salivary flow rate: ≤0.1 mL/minute scores 1 point 1
• Baseline measurement of salivary gland function should be performed before initiating treatment 5
• Salivary scintigraphy may be considered 5

Histopathological Confirmation

Minor salivary gland biopsy (3 points toward diagnosis):

• Focal lymphocytic sialadenitis with focus score ≥1 foci/4 mm² 1, 3
• Should be considered if clinical suspicion remains high despite negative or equivocal serologies 1
• All patients in definite primary Sjögren's show round cell infiltrates ≥2+ on histology 6

Diagnostic Scoring System

ACR/EULAR Classification Criteria (≥4 points required for diagnosis):

• Anti-SSA/Ro antibody positive: 3 points 1
• Focal lymphocytic sialadenitis (focus score ≥1): 3 points 1
• Abnormal ocular staining score: 1 point 1
• Schirmer test ≤5 mm/5 min: 1 point 1
• Unstimulated salivary flow ≤0.1 mL/min: 1 point 1

Pulmonary Evaluation (if respiratory symptoms present)

Baseline testing for patients with chronic cough, dyspnea, or xerotrachea:

• High-resolution CT chest with expiratory views 1, 2
• Complete pulmonary function testing (spirometry, lung volumes, DLCO) 1, 2
• Oximetry at rest and with exercise 1

Rationale: Up to 38% of Sjögren's patients develop chronic cough, and 10-20% develop interstitial lung disease over time 1, 2

Red Flags Requiring Urgent Investigation

Monitor for lymphoma development (~5% lifetime risk):

• Unexplained weight loss, fevers, or night sweats 1, 2
• New or progressive lymphadenopathy (especially head/neck) 1, 2
• Pulmonary nodules >8 mm 2
• Progressive parotid gland enlargement 2
• Low complement C4 levels at diagnosis indicate higher lymphoma risk 1, 3

Essential Referrals

Mandatory rheumatology consultation:

• Required due to 5% lifetime lymphoma risk and potential systemic complications 1
• Rheumatologist maintains overall disease coordination 1
• Co-management with ophthalmology and dentistry is essential 3, 4

Neurology consultation if:

• Peripheral neuropathy with significant sensory or motor deficits 1
• Myopathy with weakness limiting mobility 1
• Any central nervous system manifestations 1

Common Diagnostic Pitfalls

Medication-induced sicca must be excluded:

• Antihistamines, diuretics, antidepressants, and anticholinergics can mimic Sjögren's symptoms 1
• These medications should be avoided in confirmed Sjögren's patients 2

Differential diagnoses to consider:

• HCV-related sicca syndrome (differentiated by absence of anti-SSA/SSB antibodies) 3
• Checkpoint inhibitor-induced sicca (only 20% have anti-Ro antibodies) 3
• IgG4-related disease (gland enlargement more prominent than sicca symptoms) 1

Atypical presentations:

• 2.19% of Sjögren's patients lack sicca symptoms, presenting instead with arthralgias, parotid enlargement, Raynaud phenomenon, or lymphadenopathy 7
• These patients are younger and have 100% anti-Ro/SSA positivity 7
• Approximately 10% of patients with clinically significant dry eye have underlying Sjögren's syndrome 1